Copaxone Continues Cleaning Tysabri’s Clock in US Market—Maybe
[Updated for 4Q09 Copaxone sales.]
The US market is the one of consequence for MNTA investors insofar as this is where MNTA and partner NVS have submitted an application to market generic Copaxone. Below are Tysabri and Copaxone US sales for the past six quarters as well as the year-over-year and quarter-over-quarter growth rates. Copaxone is outselling Tysabri in the US by about 4:1 and it has much the higher YoY growth rate; however, US Copaxone sales appear to have topped out in 3Q09, clouding the picture.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.